CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Hydromorphonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01207596
NCT01207596Phase 4Completed
CompareCT.gov

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain: An Open Label Study

International Clinical Research Institute·interventional·Posted Sep 23, 2010·Updated Jun 20, 2012

In Brief

A Phase 4 clinical trial evaluating Hydromorphone for Neuropathic Pain. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if Exalgo (r) is beneficial for the patients with neuropathic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2010
Enrollment StartSep 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.8 years ago

Interventions

Hydromorphonedrug

Oral hydromorphone extended release, once daily